Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance
- PMID: 15020616
- DOI: 10.1200/JCO.2004.10.041
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance
Abstract
The development of malignant disease might be seen as a failure of immune surveillance. However, not all tumors are naturally immunogenic, and even among those that are immunogenic, the uncontrolled rapid growth of a tumor may sometimes out-run a robust immune response. Nevertheless, recent evidence suggests that mechanisms of tolerance that normally exist to prevent autoimmune disease may also preclude the development of an adequate antitumor response and that tumors themselves have the ability to thwart the development of effective immune responses against their antigens. A major challenge has been to develop approaches to breaking this tolerance in tumor-bearing hosts, and recent advances in our understanding of antigen presentation and tolerance have led to some promising strategies. An alternative approach is to use T cells from nontumor-bearing, allogeneic hosts in the form of lymphocyte infusions, with or without hematopoietic cell transplantation. Immunotherapy may occur in this setting via the response of nontolerant, tumor antigen-specific T cells from nontumor-bearing hosts or via the powerful destructive effect of an alloresponse directed against antigens shared by malignant cells in the recipient. Approaches to exploiting this beneficial effect without the deleterious consequence of graft-versus-host disease in allogeneic hematopoietic cell recipients are discussed.
Similar articles
-
[Antitumor immunity and cellular cancer therapies].Med Sci (Paris). 2003 Jan;19(1):43-53. doi: 10.1051/medsci/200319143. Med Sci (Paris). 2003. PMID: 12836191 Review. French.
-
Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?Arch Immunol Ther Exp (Warsz). 2002;50(3):197-224. Arch Immunol Ther Exp (Warsz). 2002. PMID: 12098935 Review.
-
Tumor resistance to CD8+ T cell-based therapeutic vaccination.Arch Immunol Ther Exp (Warsz). 2007 Jul-Aug;55(4):205-17. doi: 10.1007/s00005-007-0029-3. Epub 2007 Jul 23. Arch Immunol Ther Exp (Warsz). 2007. PMID: 17659376 Review.
-
Tumor-host immune interactions and dendritic cell dysfunction.Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7. Adv Cancer Res. 2004. PMID: 15530555 Review.
-
Cancer immunogene therapy.Arch Immunol Ther Exp (Warsz). 2001;49(5):337-43. Arch Immunol Ther Exp (Warsz). 2001. PMID: 11798131 Review.
Cited by
-
Prolonged overall survival in gastric cancer patients after adoptive immunotherapy.World J Gastroenterol. 2015 Mar 7;21(9):2777-85. doi: 10.3748/wjg.v21.i9.2777. World J Gastroenterol. 2015. PMID: 25759549 Free PMC article.
-
Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.PLoS One. 2013 May 9;8(5):e62924. doi: 10.1371/journal.pone.0062924. Print 2013. PLoS One. 2013. PMID: 23671644 Free PMC article.
-
Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.Biomed Res Int. 2015;2015:367354. doi: 10.1155/2015/367354. Epub 2015 Jun 16. Biomed Res Int. 2015. PMID: 26161397 Free PMC article. Review.
-
From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.Clin Dev Immunol. 2011;2011:439053. doi: 10.1155/2011/439053. Epub 2011 Dec 8. Clin Dev Immunol. 2011. PMID: 22190971 Free PMC article. Review.
-
Immunotherapy of childhood cancer: from biologic understanding to clinical application.Curr Opin Pediatr. 2010 Feb;22(1):2-11. doi: 10.1097/MOP.0b013e3283350d3e. Curr Opin Pediatr. 2010. PMID: 19952749 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources